Parliament Workbench
Data: Motions & questions to 19 Nov 2026

General Question · S1O-06417 · Session 1

What progress it is making in assessing the suitability of prescribing beta interferon and glatiramer acetate to people with multiple scler…

Answered Asked by Shona Robison SNP Lodged 29 Jan 2003

The question

To ask the Scottish Executive what progress it is making in assessing the suitability of prescribing beta interferon and glatiramer acetate to people with multiple sclerosis.

The answer

Answered by Frank McAveety on 6 Feb 2003

NHS boards are required to make the necessary arrangements to ensure that their patients with multiple sclerosis who meet criteria set out by the Association of British Neurologists can receive treatment with beta interferon or glatiramer acetate under the risk-sharing scheme.Data collected under the scheme is maintained by the scheme co-ordinator, Sheffield University's School of Health and Related Research (ScHARR). ScHARR has advised that specialist centres in Scotland are prescribing under the scheme.

In the Official Report

No contribution in the Official Report cites S1O-06417 by reference.